Repligen (RGEN) Competitors

Biogen (NASDAQ:BIIB) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability.

Does the media prefer BIIB or RGEN?

In the previous week, Biogen had 23 more articles in the media than Repligen. MarketBeat recorded 32 mentions for Biogen and 9 mentions for Repligen. Biogen's average media sentiment score of 1.34 beat Repligen's score of 1.28 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	24 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, BIIB or RGEN?

Biogen has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.

Is BIIB or RGEN more profitable?

Biogen has a net margin of 16.87% compared to Repligen's net margin of -4.64%. Biogen's return on equity of 14.98% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Repligen	-4.64%	4.21%	2.94%

Do analysts recommend BIIB or RGEN?

Biogen presently has a consensus price target of $191.30, indicating a potential upside of 46.53%. Repligen has a consensus price target of $173.25, indicating a potential upside of 35.79%. Given Biogen's higher possible upside, equities analysts clearly believe Biogen is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
Repligen	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

Do insiders and institutionals have more ownership in BIIB or RGEN?

87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 1.2% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable valuation and earnings, BIIB or RGEN?

Biogen has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.82B	1.95	$1.63B	$10.13	12.89
Repligen	$650.43M	11.02	$35.60M	-$0.45	-283.53

Does the MarketBeat Community believe in BIIB or RGEN?

Biogen received 1406 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 67.09% of users gave Repligen an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1824 71.28%	Underperform Votes 735 28.72%
Repligen	Outperform Votes 418 67.09%	Underperform Votes 205 32.91%

Summary

Biogen beats Repligen on 13 of the 18 factors compared between the two stocks.